FDA Approves Vera Therapeutics' TRUTAKNA for Kidney Disease
A New Weapon Against a Silent Kidney Disease
On July 7, 2026, the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, known scientifically as atacicept-vymj, developed by Vera Therapeutics.
The approval targets primary immunoglobulin A nephropathy, or IgAN, an immune-mediated kidney disease and one of the leading causes of chronic kidney disease worldwide.
TRUTAKNA is indicated to reduce proteinuria, the abnormal leakage of protein into urine, in adults with IgAN who are at risk of disease progression.
Vera Therapeutics describes it as the first and only approved therapy that simultaneously inhibits both BAFF and APRIL, two proteins that drive the faulty immune response behind this disease.
Understanding IgA Nephropathy
IgA nephropathy was first described in 1968 by French pathologist Jean Berger, and it remains one of the most common forms of primary glomerulonephritis worldwide.
The disease develops when immune complexes containing immunoglobulin A deposit in the kidney's filtering units, the glomeruli, triggering inflammation and progressive scarring.
Global incidence is estimated at roughly 2.5 cases per 100,000 people per year, though rates vary sharply by region and are notably higher across parts of Asia, with Japan alone estimated to have around 350,000 biopsy-confirmed cases.
According to Vera Therapeutics, approximately 160,000 patients in the United States are affected, making IgAN the most frequently diagnosed primary glomerular disease among adults.
Left unchecked, the disease carries an unusually high lifetime burden: at least half of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.
Why Proteinuria Matters So Much
Proteinuria is not just a symptom of IgAN, it is one of the strongest known predictors of how quickly a patient's kidney function will decline.
That is precisely why regulators accepted proteinuria reduction as the basis for accelerated approval, a pathway reserved for therapies addressing a serious, unmet medical need through a biomarker reasonably likely to predict clinical benefit.
Inside the ORIGIN 3 Trial Data
The FDA's decision rests on a prespecified interim analysis of the ongoing Phase 3 ORIGIN 3 trial, covering the first 203 participants who received at least one dose of TRUTAKNA or placebo.
At 36 weeks, patients treated with TRUTAKNA achieved a 46 percent reduction in proteinuria from baseline, compared with a 42 percent reduction relative to placebo, a result statistically significant at p less than 0.0001.
The safety profile across the broader ORIGIN clinical program was described as generally favorable and comparable to placebo, with the most common adverse reactions being infections and mild reactions at the injection site.
Full trial results were published in the New England Journal of Medicine, reinforcing the scientific rigor behind the regulatory decision.
What Accelerated Approval Does and Does Not Confirm
It is worth being precise about what this approval establishes. Accelerated approval is based specifically on the reduction of proteinuria, and it has not yet been established whether TRUTAKNA slows the long-term decline of kidney function itself.
Continued approval will depend on verifying real clinical benefit through the trial's confirmatory endpoint, changes in estimated glomerular filtration rate, or eGFR, with results expected in the third quarter of 2026.
Vera Therapeutics has already aligned with the FDA on a revised, earlier eGFR analysis timeline, following input from a National Kidney Foundation workshop involving clinicians, researchers, regulators, and patient advocates.
How TRUTAKNA Works
TRUTAKNA is delivered as a once-weekly 150 milligram subcutaneous injection using an autoinjector, designed for patients to administer at home.
Its mechanism targets two signaling proteins, BAFF and APRIL, both of which drive the survival and activity of the antibody-producing cells responsible for the abnormal IgA immune complexes seen in this disease.
By blocking both pathways simultaneously rather than just one, the drug is designed to reduce the underlying immune drivers of the disease rather than only managing its downstream symptoms.
Mechanism
Dual inhibition of BAFF and APRIL, the immune signaling proteins that drive abnormal IgA antibody production in the kidney.
Administration
Once-weekly 150 mg subcutaneous injection via a self-administered autoinjector.
Trial Result
46% reduction in proteinuria from baseline and 42% versus placebo at 36 weeks in the ORIGIN 3 interim analysis.
Where TRUTAKNA Fits in the Treatment Landscape
Until recently, IgAN had no disease-specific approved therapies at all, leaving physicians to rely on blood pressure control, supportive care, and broader immunosuppressive strategies.
That began changing only in the past few years with the arrival of targeted options such as budesonide-based and endothelin-receptor-targeting therapies, which approach the disease through different biological pathways than TRUTAKNA's dual BAFF and APRIL inhibition.
Vera Therapeutics has indicated it intends to pursue atacicept in expanded IgAN patient populations and in other related autoimmune kidney diseases, including membranous nephropathy and focal segmental glomerulosclerosis.
That pipeline ambition echoes a broader pattern we highlighted in our recent coverage of how a single kidney-focused drug mechanism can extend into heart failure and metabolic disease, underscoring how modern nephrology increasingly treats kidney, immune, and cardiovascular pathways as interconnected rather than isolated.
What This Means for Patients and the Market
For patients, the approval offers a genuinely new mechanism of action rather than an incremental variation on existing options, arriving through the FDA's Breakthrough Therapy and Priority Review pathways that Vera Therapeutics secured earlier in its development.
For clinicians and payers, the drug adds a new decision point to an already evolving IgAN treatment landscape, with managed care organizations expected to track how it is positioned relative to existing therapies as more data matures.
For Vera Therapeutics, now describing itself as a commercial-stage biotechnology company, TRUTAKNA becomes its flagship product as it pursues full approval later this year pending the confirmatory eGFR results.
What Comes Next
The most important open question is not whether TRUTAKNA lowers proteinuria, the interim data already answers that, but whether that reduction translates into genuinely preserved kidney function over years, not just weeks.
Those eGFR results, expected in the third quarter of 2026, will determine whether TRUTAKNA advances from accelerated to full approval and whether its early promise holds up against the disease's notoriously slow, decades-long course.
Until then, TRUTAKNA stands as a conditionally approved, biologically novel option for a serious kidney disease that, until very recently, had few targeted treatments to offer.
.jpg)
.jpg)
0 Comments